Invention patent for IMM40H was authorized by the US Patent and Trademark Office

    On November 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly developed humanized IgG1 anti- CD70 monoclonal antibody (project number: IMM40H) has been authorized by the US Patent and Trademark Office (APPLICATION No.: US 17/685,501). As one of the most important pharmaceutical markets in the world,  the patent authorization in USA will greatly improve the global market competitiveness of the project. The patent authorization and approval of the IMM40H project in China, Japan, Europe and other countries/regions is also in progress.

    Previously, IMM40H was approved by the Chinese NMPA and the US FDA for clinical research, marking another milestone in the development of CD70-targeting drug by ImmuneOnco.

    CD70 highly expresses in solid and hematological tumors.  Its ligand CD27 expresses in regulatory T (Treg) cells, and CD70-CD27 interaction can activate Treg cells which inhibit immune responses. In vitro experimental data show that IMM40H has superior affinity to CD70 and block CD70/CD47 interaction better and has more powerful cancer killing activities than other similar candidate antibodies in public patents. In vivo pharmacodynamic studies also demonstrated that IMM40H had significant inhibitory activity against a variety of tumors. Subcutaneously implanted myeloma can be eliminated completely after 2-3 dosing at low dosage.

Dr. Tian, Wenzhi, founder and chairman of ImmuneOnco, said:

    "I am very pleased that the invention patent of our IMM40H project has been authorized by the US Patent and Trademark Office. We believe that IMM40H has great value for clinical development. We will actively promote clinical trials and strive to bring it to the market, so as to benefit cancer patients as soon as possible. "